Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

References

• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13:1–14.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
   PubMed Web of Science ®Google Scholar
• Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531–4.
   PubMed Web of Science ®Google Scholar
• Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660–4.
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81–3.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448–54.
   PubMed Web of Science ®Google Scholar
• Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104:241–7.
   PubMed Web of Science ®Google Scholar
• Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351–5.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69(4):669–72.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3):534–44.
   PubMed Web of Science ®Google Scholar
• Riesenbeck LM, Bierer S, Hoffmeister I, Ko¨pke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29(6):807–13.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol. 2012;23(3):714–21.
   PubMed Web of Science ®Google Scholar
• Rini B. Kidney cancer: does hypothyroidism predict clinical outcome? Nat Rev Urol. 2011;8(1):10–11.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Andersen S, Bulow PI, Carle A. Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging. 2005;22:23–38.
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560–76.
   PubMed Web of Science ®Google Scholar
• Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid. 2008;18(7):809–12.
   PubMed Web of Science ®Google Scholar
• Mukku VR. Regulation of epidermal growth factor receptor levels by thyroid hormone. J Biol Chem. 1984;259(10):6543–7.
   PubMed Web of Science ®Google Scholar
• Wolf M, Ingbar SH, Moses AC. Thyroid hormone and growth hormone interact to regulate insulin-like growth factor-I messenger ribonucleic acid and circulating levels in the rat. Endocrinology. 1989;125(6):2905–14.
   PubMed Web of Science ®Google Scholar
• Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146(7):2864–71.
   PubMed Web of Science ®Google Scholar
• Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 2012;30(5):704–10.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell carcinoma. J Clin Oncol. 2008;26(Suppl):280s. [Abstr 5126].
   Google Scholar
• Sella A, Hercbergs AH, Hanovich E, Kovel S. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Chemotherapy. 2012;58(3):200–5.
   PubMed Web of Science ®Google Scholar
• Garfield DH, Wolter P, Schöffski P, Hercbergs A, Davis P. Documentation of thyroid function in clinical studies with sunitinib; why does it matter? J Clin Oncol. 2008;26(31):5131–2.
   PubMed Web of Science ®Google Scholar
• Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol. 2007;4(12):674–5.
   PubMedGoogle Scholar
• Houk B, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, et al. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure response for sunitinib in metastatic renal cell carcinoma (mRCC) [abstract]. Eur J Cancer. 2007;5(Suppl):299. [Abstract 4505].
   Google Scholar
• Puzanov I, Michaelson MD, Cohen DP, Li S, Burnett P, Desai J. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J Clin Oncol 2011;29(suppl). abstract e21113.
   Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–73.
   PubMed Web of Science ®Google Scholar
• Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P. Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients. BJU Int. 2014; Sep 23. doi: 10.1111/bju.12940.
   Web of Science ®Google Scholar